Mechanistically, M2 enhances tumor survival via pathways like CCL2/PI3K/Akt/mTOR in breast cancer, IL-6/STAT3 in colon and pancreatic cancers, and CHI3L1 in gastric/breast cancers [63,64,65,66]. Here, AKT1 is linked to familial pancreatic carcinoma.